

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A method of treating an individual having a pathophysiological state selected from the group consisting of ~~acute myeloid leukemia, acute promyelocytic leukemia, lymphomas, myelomas, and drug-resistant leukemias, lymphomas, and myelomas~~, comprising the steps of:

a). administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen; and,

b). administering to the same individual a pharmacologically effective dose of an immunotoxin directed against the up-regulated CD38 antigen.

2.-4. (Cancelled)

5. (Previously Presented) The method of claim 1, wherein said retinoid is a material selected from the group consisting of all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-*cis* RA); (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (E)-4-[2-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1- propenyl]benzoic acid (3-met TTNPB).

6. (Original) The method of claim 5, wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

7. (Previously Presented) The method of claim 1, wherein said immunotoxin specifically targets cells expressing the CD38 antigen.

8. (Original) The method of claim 7, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

9. (Original) The method of claim 8, wherein said toxin is gelonin.

10. (Cancel)

11. (Original) The method of claim 1, wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

12. (New) The method of claim 1, wherein said pathophysiological state comprises drug-resistant leukemia.

13. (New) The method of claim 12, wherein said drug-resistant leukemia is adriamycin-resistant leukemia.

14. (New) The method of claim 1, wherein said pathophysiological state comprises lymphoma.

15. (New) The method of claim 1, wherein said pathophysiological state comprises myeloma.